First-line tislelizumab plus chemotherapy versus placebo plus chemotherapy in unresectable advanced/metastatic esophageal squamous cell carcinoma: minimum 3-year survival follow-up of a randomized phase 3 trial (RATIONALE-306)
- Harry H. Yoon
- Ken Kato
- Eric Raymond
- Richard Hubner
- Yongqian Shu
- Yueyin Pan
- Sook Ryun Park
- Takashi Kojima
- Chen-Yuan Lin
- Lucjan Wyrwicz
- David Tougeron
- Ryu Ishihara
- Kaijun Wang
- Yanyan Peng
- Jianming Xu
2026-09-03